Epidemiology and Prognosis of Encephalitis in Intensive Care

Encephalitis Clinical Trial

— ENCEPHALITICA  

Official title:

Epidemiology and Prognosis of Encephalitis in Intensive Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02906631
• Other study ID #: AOR 15096
• Status: Completed
• Start date: October 27, 2017
• Est. completion date: December 1, 2023

Study information

• Verified date: March 2024
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Introduction: Acute encephalitis (AE) is a severe neurological disorder associated with significant morbidity and mortality. Approximately 50% of patients with AE require ICU admission because of coma, seizures or acute respiratory failure. Determinants of neurological prognosis in these patients are not known.

Objectives:

Main objective: To identify determinants of outcome in adult patients admitted to the ICU; Secondary objectives: a) To study the impact of diagnostic studies (Brain MRI, CSF analysis, EEG) on neurologic outcome; b) to describe the epidemiology of patients admitted to the ICU with AE; c) to study the impact of early appropriate therapy on neurologic outcomes; d) to describe morbidity and mortality associated with AE at 90 days and 1 year following diagnosis.

Methods: prospective observational multicenter study in French ICUs. All patients admitted to the ICU for probable or confirmed AE (2013 IDSA criteria)with a Glasgow coma scale score < or =to 13 will be eligible for inclusion. Factors associated with a poor prognosis at 90 days will be identified by multivariable logistic regression analysis.

Duration of study: 30 months (recruitment 18 months, follow-up 12 months).

Patients: 300 patients

Endpoints:

• Primary endpoint: The primary endpoint is the modified Rankin scale score 90 days following onset of abnormal status (GCS < or =13). This score will be determined by contacting the patient. A poor outcome will be defined as a mRS >2 at 90 days.

• Secondary endpoints: a) neurological findings within 7 days following onset of altered mental status; b) abnormal findings on diagnostic studies (MRI, EEG, CSF analysis) within7 days following onset of altered mental status; c) Time between onset of altered mental status and completion of diagnostic studies; d)Time between onset of altered mental status and start of appropriate specific therapy; e) neurologic outcomes at 1 year mRS score and extended Glasgow outcome scale (GOS); f) causes of death in non-survivors at 1 year; g) quality of life and posttraumatic stress at 1 year: IADL and SF36 scales;

Description:

Acute encephalitis (AE) is a serious condition associated with significant morbidity and mortality. Patients require ICU admission in 60 % of cases, mainly because of neurological symptoms (coma, seizures) or acute respiratory failure.

The etiological profile of AE has changed considerably in recent years, with the emergence of new pathogens and the description of new immune-mediated causes (acute disseminated encephalomyelitis (ADEM), autoimmune limbic encephalitis) that require urgent specific therapies. Furthermore, despite extensive investigations, the proportion of cases of unknown cause remains high.

In-ICU care of patients with AE is a difficult task, given the diversity of etiologies and clinical presentations. Furthermore, additional studies such as magnetic resonance imaging (MRI) can be challenging to obtain in this population. Finally, there are no specific recommendations on the management and prognostic assessment of patients admitted to the ICU with AE.

Present available data on the prognosis of patients with AE include both adult and pediatric cases, and focuses only on AE with identified causes. Prognosis of encephalitis in adult patients requiring ICU admission has been previously described only in retrospective single centre cohorts. To date, no prospective multicenter study on AE has been conducted in the specific population of adult critically ill patients. Furthermore, data on the diagnostic and prognostic contributions of magnetic resonance imaging (MRI) and electroencephalography studies in these patients are lacking The development of guidelines for standardized care in critically ill AE patients is needed, and will include management of early life support, prompt and exhaustive etiologic investigations, early administration of specific treatments and assessment of neurological prognosis. This study, which will focus on prognostic evaluation of severe AE in adults, appears crucial to support the development of such guidelines.

Patients admitted to ICU for a suspicion of AE (acute encephalopathy and CSF pleocytosis > 5 cells / microliter) will be eligible for inclusion.

Patients admitted to ICU for a suspicion of AE (acute encephalopathy and CSF pleocytosis > 5 cells / microliter) will be eligible for inclusion. Eligible patients will be included if they fulfil the IDSA 2013 diagnostic criteria for ""probable"" or ""confirmed"" encephalitis (see inclusion criteria). In patients without an obvious etiological diagnosis, an algorithm will be suggested to investigators to guide etiological investigations, according to the most recent recommendations (IDSA 2013). Aetiology of encephalitis will be described according to a priori-defined categories: 1) viral causes, 2) immune-mediated-causes, 3) bacterial or fungal meningitis with secondary encephalitic features, 4) undetermined causes. For each included patient, CSF and plasma samples will be stored at -80°C. A biobank will be created for subsequent analyses (etiological diagnosis, prognostic biomarkers). Outcomes will be assessed at 90 days and 365 days by contacting the patient or his relatives. The primary outcome is the score on the modified Rankin scale, which will be assessed 90 days after inclusion. Independent predictors of functional outcomes will be determined by multivariate logistic regression analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 350
• Est. completion date: December 1, 2023
• Est. primary completion date: April 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Altered mental status, delirium, or personality changes for a duration > or = 24 h

• At least 2 of the following: 1) fever (>38°C) within 72 hours before or following hospital admission; 2) new-onset seizures; 3) new-onset focal signs; 4) CSF pleocytosis > 5 cell / microl; 5) brain parenchyma abnormalities on neuroimaging compatible with the diagnosis of encephalitis; 6) EEG abnormalities compatible with the diagnosis of encephalitis.

• Altered mental status with a GCS < or =13 without sedation, or GCS < or =13 before sedation administration in sedated patients

• CSF analysis performed

• Brain imaging performed (CT/MRI)

• Age >18

Exclusion criteria:

• Time between the first hospitalization for neurologic symptoms in relation with encephalitis and ICU admission > 21 days

• Purulent bacterial meningitis diagnosed by direct examination or CSF analysis

• Isolated brain abscess.

• Febrile encephalopathy associated with another diagnosis

• Predicted time in ICU < or = 24 hours

• Opposition of close-of-kin, if present at the inclusion, for patient participation in research.

Related Conditions & MeSH terms

• Encephalitis

Locations

Country	Name	City	State
France	Hôpital Bichat-Claude Bernard	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neurological status on the modified Rankin scale	The primary outcome measure is the modified Rankin scale score 90 days following onset of abnormal status (defined by a GCS score< or =13). This score will be determined by contacting the patient or his relatives. A poor outcome will be defined as a mRS >2 at 90 days.	90 days
Secondary	Biological data within 7 days following onset of altered mental status		7 days
Secondary	State of consciousness defined by the Glasgow Coma Scale within 7 days following onset of altered mental status		7 days
Secondary	Patient's comorbidity measured by Charlson Comorbidity Index		7 days
Secondary	Presence of focal neurological deficit within 7 days following onset of altered mental status		7 days
Secondary	Presence of thermal dysregulation within 7 days following onset of altered mental status		7 days
Secondary	Presence of seizures within 7 days following onset of altered mental status		7 days
Secondary	Magnetic resonance imaging anomalies within 7 days following onset of altered mental status		7 days
Secondary	Electrophysiologic anomalies within 7 days following onset of altered mental status		7 days
Secondary	Time between onset of altered mental status and cerebrospinal fluid analysis		one year
Secondary	Time between onset of altered mental status and brain magnetic resonance imaging study		one year
Secondary	Time between onset of altered mental status and electroencephalogram study		one year
Secondary	Time between onset of altered mental status and completion of diagnostic studies (CSF analysis, MRI, EEG)		one year
Secondary	Number of patients with primitive acute encephalitis (AE)	Number of patients with infectious causes leading to primitive AE	7 days
Secondary	Number of patients with infectious causes leading to meningitis with secondary encephalitic features		7 days
Secondary	Number of patients with immune-mediated causes of encephalitis		7 days
Secondary	Number of patients with other infectious causes of encephalitis		7 days
Secondary	Proportion of patients with appropriate specific therapy		7 days
Secondary	Time between onset of altered mental status and appropriate specific therapy		one year
Secondary	Neurological status on the modified Rankin scale	This score will be determined by contacting the patient or his relatives.	365 days
Secondary	Hospital anxiety and depression scale (HAD)		365 days
Secondary	Quality of life measured by SF36 scale		365 days
Secondary	INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE (IADL)		365 days
Secondary	Neurological prognosis on the extended Glasgow outcome scale		365 days